Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca to invest $2bn in Summit for ADC combination therapies
AstraZeneca and Summit agreed to a clinical collaboration to assess ivonescimab in combination with sonesitatug vedotin. Credit: Jose Eduardo Rubio / Shutterstock.com.
AstraZeneca and Summit agreed to a clinical collaboration to assess ivonescimab in combination with sonesitatug vedotin. Credit: Jose Eduardo Rubio / Shutterstock.com.